Interview with Wolfgang Söhngen, CEO, Paion
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
Address: Heimeranstrasse 35, Munich,Germany
Tel: +49 89 893119-0
FGK clinical research is a full service contract research organisation offering a complete range of clinical development and consulting services to pharmaceutical, biotechnology and medical device companies.With more than 50 highly skilled and experienced people, FGK operates out of Munich on local and global projects, covering clinical studies from phases I to IV. FGK has extensive experience in all major therapeutic areas and clinical research fields, which allows it to effectively design, manage and analyze its clients’ development programs and clinical trials.FGK works with a network of carefully selected partner companies to provide a range of services to complement its own. The company therefore offers monitoring services all over Europe and the US. It is also able to provide you access to and expertise in leading EDC technologies, which helps provide high-quality clinical trial data in the shortest possible time.FGK also provides expertise in global product development and statistical and regulatory compliance in order to assist biotech and medical device companies in the design and execution of adequate clinical studies and global development strategies.
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the…
You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different experiences enable you to…
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for…
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
See our Cookie Privacy Policy Here